Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, announced that is has completed a successful pre-Investigational New Drug exemption (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound, Kevetrin, which is being developed to treat drug resistant cancers. The Company has the remaining pre-IND animal studies for Kevetrin underway… (Source: Health News from Medical News Today)

Further information:

Article source

Related posts:

1. Biomodels’ Oral Mucositis Expertise Speeds Up FDA Approval for ActoGeniX’s Phase 1b Trial of AGO13 in Cancer Patients
2. Cellectar Completes Enrollment In Phase I Clinical Trial Of Lead Drug Candidate (131)I-CLR1404 For The Treatment Of Solid Malignancies
3. FDA Approves Beech Tree Labs’ Influenza IND Application
4. FDA Sets March 22 For ODAC Meeting To Review CTI’s New Drug Application For Pixantrone
5. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report